The Brief Summary
The Brief Summary is a monthly bulletin intended for all OPDP stakeholders. Started in January 2022, The Brief Summary provides news and updates related to OPDP. Subscribe to The Brief Summary here and join the "Prescription Drug Promotion" listserv.
OPDP’s Social Science Research Program: Aiming to Understand How Health Care Providers and Patients Interpret Prescription Drug Information
FDA notifies Amgen of misbranding of its biological product, Neulasta, due to false or misleading promotional communications about the product’s benefit
FDA issues warning to AcelRx for making false and misleading claims about the risks and benefits of Dsuvia
OPDP Reflects on 2020, Looks Forward to 2021 as It Helps Ensure Prescription Drug Promotion Is Truthful, Balanced and Accurate | FDA
Core Launch Updates
On November 20, 2020, OPDP hosted a webinar to provide an overview of the upcoming changes to the OPDP Core Launch Review process. The webinar will provide information to:
- Identify promotional materials that qualify for Core Launch Review within the OPDP Advisory Process
- Understand the changes to the Core Launch Review process and incorporate those changes into existing promotional material development strategies
- Utilize the various resources provided by OPDP to support the Core Launch Review process
The recorded webinar is available at the link below.